newsfilter
← Latest News
GlobeNewswire·

BioStem Technologies Reports Second Quarter 2026 Financial Results

BSEM
  • BioStem Technologies generated $7.9 million in net revenue for Q2 2026, representing 29% sequential growth from $6.1 million in Q1 2026.
  • The company raised its full-year 2026 revenue guidance to a range of $26 million to $29 million, up from the previous range of $25 million to $29 million.
  • BioStem successfully uplisted its common stock to the Nasdaq Capital Market on August 7, 2026.
  • The company completed a $2.5 million private placement with its first institutional investor.
  • Q2 2026 gross profit totaled $4.8 million with a gross margin of 61%, while operating expenses increased to $13.2 million.
  • GAAP net loss for the quarter was $9.0 million ($0.52 per share), compared to a net income of $10,613 in Q2 2025.
  • Adjusted EBITDA loss for the quarter was $4.6 million, compared to an adjusted EBITDA profit of $2.5 million in Q2 2025.
  • Cash and cash equivalents stood at $7.0 million as of June 30, 2026, down from $13.7 million at the end of Q1 2026.
  • Hospital revenue reached $6.7 million in Q2 2026, while physician office revenue was $1.1 million.
  • BioStem issued eight new U.S. design patents covering fenestrated human placental allograft technology.
  • The company expanded its commercial organization, integrated CRM and ERP systems, and transitioned major GPO agreements.
  • BioStem resolved $5.3 million in outstanding debt through a $3.5 million cash payment and a $1.0 million promissory note.